TORNTPHARM.NS Torrent Pharmaceuticals Limited
INR·Price 4443.60·Mkt cap 1.50TComputed from the latest reported financials and the current market price.
Who's the real player?
A genuine play on this theme — most of its business sits right here.
Is the business healthy?
A mixed picture — real strengths, but soft spots in cash flow, returns or debt.
- ⚠Receivables growing much faster than revenue (channel-stuffing risk)
- High cash flow quality
- Positive FCF conversion
- Strong profitability margins
Are the smart people buying?
No ownership-change data for this stock. Conviction is judged from capex and buyback signals alone.
- High promoter/insider ownership
- Significant insider net buys
- Capex growth indicates future belief
What is management saying?
No earnings-call transcript or filings found for this stock.
Is the price right?
Intrinsic value 1038.48 vs price 4443.60 — screens expensive on a cash-flow DCF (-76.6% to intrinsic). The base FCF growth assumption of 9.34% is plausible but should be compared with historical performance and industry trends for validation.
| Intrinsic / share | 1038.48 |
| Price | 4443.60 |
| Upside to intrinsic | -76.6% |
| Reverse-DCF implied g | 26.0% |
Base FCF 23.84B · growth 9.3% · discount 12.0% · terminal 5.0%.
Sensitivity — intrinsic value / share
Each cell is the intrinsic value at that growth (across →) and discount rate (down ↓). Center ★ is the base case. Cells green = above price (cheap), red = below (expensive).
| Growth rate → | |||||
|---|---|---|---|---|---|
| Disc ↓ ╲ g | 5% | 7% | 9% | 11% | 13% |
| 10% | 1107.95 | 1364.21 | 1663.37 | 2011.95 | 2417.36 |
| 11% | 853.59 | 1059.03 | 1298.23 | 1576.32 | 1899.07 |
| 12% | 671.97 | 841.53 | ★ 1038.48 | 1266.91 | 1531.46 |
| 13% | 535.81 | 678.82 | 844.51 | 1036.26 | 1257.86 |
| 14% | 429.95 | 552.59 | 694.35 | 858.02 | 1046.79 |
Through the masters' eyes
Each investor's numeric rules, checked against this stock's metrics: exact math, no guesswork. Tap one to see which rules pass, fail, and what to judge yourself.
▶
Passes 2 of 3 of Rakesh Jhunjhunwala's numeric checks. Still judge the non-numeric criteria below for yourself.
- ROE ≥ 18% — now 25.8%
- Net margin ≥ 10% — now 15.7%
- Conservative leverage (D/E ≤ 1.0) — now 1.79
- A large, scalable opportunity
- Trustworthy, ambitious management
- Conviction to hold through volatility
Couldn't check from available data: Earnings growth ≥ 15% — not available
▶
Passes 3 of 5 of Warren Buffett's numeric checks. Still judge the non-numeric criteria below for yourself.
- ROE ≥ 15% — now 25.8%
- Net margin ≥ 10% — now 15.7%
- Positive free cash flow — now 17.1%
- Conservative leverage (D/E ≤ 1.0) — now 1.79
- Trades below intrinsic value (margin of safety ≥ 0) — now -327.9%
- A business you can understand
- A durable competitive moat
- Honest, capable management
▶
Passes 2 of 4 of Radhakishan Damani's numeric checks. Still judge the non-numeric criteria below for yourself.
- Consistent revenue (consistency ≥ 80%) — now 94%
- Positive net margin — now 15.7%
- High returns on capital (ROCE ≥ 18%) — now 9.6%
- Very low debt (D/E ≤ 0.5) — now 1.79
- A durable consumer franchise
- Pricing power
- A long runway, bought patiently
▶
Passes 1 of 2 of Raamdeo Agrawal's numeric checks. Still judge the non-numeric criteria below for yourself.
- Longevity: revenue consistency ≥ 70% — now 94%
- Quality: ROCE ≥ 18% — now 9.6%
- Durability of the growth (longevity)
- Quality and honesty of management
Couldn't check from available data: Growth: earnings CAGR ≥ 15% — not available; Price: PEG ≤ 2 — not available
▶
Passes 1 of 2 of Vijay Kedia's numeric checks. Still judge the non-numeric criteria below for yourself.
- ROE ≥ 15% — now 25.8%
- Manageable debt (D/E ≤ 1.0) — now 1.79
- Ambitious, capable management
- A small company with a large opportunity
- Patience to hold for years
Couldn't check from available data: Strong earnings growth ≥ 20% — not available
▶
Passes 1 of 4 of Charlie Munger's numeric checks. Still judge the non-numeric criteria below for yourself.
- ROE ≥ 15% — now 25.8%
- High returns on capital (ROCE ≥ 15%) — now 9.6%
- Conservative leverage (D/E ≤ 1.0) — now 1.79
- Trades below intrinsic value (margin of safety ≥ 0) — now -327.9%
- A high-quality, understandable business
- A durable moat
- Management of integrity
▶
Passes 1 of 6 of Benjamin Graham's numeric checks. Still judge the non-numeric criteria below for yourself.
- Financially safe (Altman Z ≥ 3) — now 4.74
- P/E ≤ 15 — now 69.91
- P/B ≤ 1.5 — now 18.03
- Graham number: P/E × P/B ≤ 22.5 — now 1260.5
- Strong liquidity (current ratio ≥ 1.5) — now 1.13
- Debt below equity (D/E ≤ 1.0) — now 1.79
- A long record of stable earnings
- An uninterrupted dividend history
▶
Passes 0 of 2 of Peter Lynch's numeric checks. Still judge the non-numeric criteria below for yourself.
- Manageable debt (D/E ≤ 1.0) — now 1.79
- Solid liquidity (current ratio ≥ 1.5) — now 1.13
- A simple business you understand
- Which 'type' it is (fast grower, stalwart, cyclical…)
- A believable growth story
Couldn't check from available data: PEG ≤ 1 (growth cheap vs price) — not available; Earnings growth ≥ 15% — not available
Financial statements (INR)
↗ sourceCash-flow lines highlighted — we trust cash over reported profit.
| Line | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | 137.53B | 113.17B | 105.62B | 94.64B | — |
| Operating income | 34.40B | 29.26B | 25.72B | 21.40B | — |
| EBITDA | 43.76B | 37.19B | 35.00B | 28.81B | — |
| Net income | 21.63B | 19.11B | 16.56B | 12.45B | — |
| Operating cash flow | 30.23B | 25.85B | 32.66B | 23.68B | — |
| Capex | -6.77B | -6.12B | -4.33B | -5.74B | — |
| Free cash flow | 23.45B | 19.73B | 28.33B | 17.94B | — |
| Total assets | 443.12B | 149.90B | 150.61B | 150.12B | — |
| Total equity | 83.88B | 75.91B | 68.56B | 61.98B | — |
| Total debt | 150.25B | 32.02B | 40.22B | 53.69B | — |
| Cash & equivalents | 11.17B | 5.73B | 8.35B | 5.09B | — |